Prescription Drug Marketing Act
Shared Resource Enterprises, Inc.'s (SRE) member hospitals are left with excess stock, and one hospital in particular had an inventory that was 40.8% higher in September 1988 than it was in September 1987, firm maintains in Feb. 24 comments to FDA regarding agency's implementation of the Act. SRE had earlier informed FDA that hospitals "require a policy which will allow the legitimate return of excess inventory without restriction".
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.